Objective: The purpose of this study was to determine the relative distribution of omentin and visfatin mRNA in human epicardial, peri-internal mammary, upper thoracic, upper abdominal and leg vein subcutaneous adipose tissue as well as the distribution of omentin in the nonfat cells and adipocytes of human omental adipose tissue. Background: Omentin is found in human omentum but not subcutaneous fat. Omentin and visfatin are considered markers of visceral abdominal fat. Research design and methods: The mRNA content of omentin and visfatin was measured by qRT-PCR analysis of fat samples removed from humans undergoing cardiac or bariatric surgery. Results: Omentin mRNA in internal mammary fat was 3.5%, that in the upper thoracic subcutaneous fat was 4.7% while that in the other subcutaneous fat depots was less than 1% of omentin in epicardial fat. The distribution of visfatin mRNA did not vary between the five depots. Omentin mRNA was preferentially expressed in the nonfat cells of omental adipose tissue since the omentin mRNA content of isolated adipocytes was 9% of that in nonfat cells, and similar results were seen for visfatin. The amount of omentin mRNA in differentiated adipocytes was 0.3% and that of visfatin 4% of that in nonfat cells. The amount of omentin mRNA in preadipocytes was virtually undetectable while that of visfatin was 3% of that in freshly isolated nonfat cells from omental adipose tissue. Conclusion: Omentin mRNA is predominantly found in epicardial and omental human fat whereas visfatin mRNA is found to the same extent in epicardial, subcutaneous and omental fat.
Introduction
Omentin is a protein previously described as intelectin since it was found in the small intestinal Paneth cells of mice 1 and the heart, small intestine, colon and thymus of humans. 2 The lectin part of the name derived from the finding that intelectin is a soluble protein able to bind galactofuranosyl residues present in various microorganisms. 2 Omentin/ intelectin is a lipid-raft-associated protein in the intestinal brush border cells 3 and is the human homolog of the Xenopus lectin XL35. 4 In humans, omentin/intelectin is expressed in the endothelial cells of aorta, colon, liver and thymus. 4 Omentin is expressed in the omental but not the subcutaneous adipose tissue (SAT) of humans. 5, 6 The circulating levels of omentin are not directly associated with postprandial glucose in humans. 7 However, fasting circulating levels of omentin as well as omentin mRNA in omental fat are decreased in obese men as well as women. 8 This may be important since adiponectin is the only molecule reported to date whose level in adipose tissue decreases in human obesity. 9, 10 The common embryological origin of omental fat and epicardial adipose tissue 11 prompted us to question whether omentin was also present in epicardial fat. Visfatin was originally described as an adipokine present only in visceral adipose tissue. 12 Therefore, we compared visfatin and omentin mRNA content in epicardial fat with that of other adipose tissues as well as mRNA distribution between nonfat and fat cells plus preadipocytes and in vitro differentiated adipocytes derived from omental adipose tissue. The studies had the approval of local institutional review boards and all patients involved gave their informed consent.
Research design and methods

Patients
Fat samples
Fat (0.2-1 g) was obtained after opening the thorax but before heparinization and cardiopulmonary bypass, from: (1) epicardial fat as close as possible to the origin of the right coronary artery at the base of the heart, (2) subcutaneous (SAT) anterior upper thoracic fat from the sternotomy incision at the manubrium sterni (SAT m. sterni), (3) fat from the inner chest wall around the internal mammary artery (IMA) between its mid course and the diaphragm, (4) SAT from the abdominal wall at the lower sternotomy incision (SAT abdominal), and (5) Relative quantification of the data was based on the comparative Cp method resulting in the ratio of mRNA between two fractions that eliminates the need for standard curves. The arithmetic formula to calculate ratios from DDCp is based on a log 2 scale (2
ÀDDCp
). This procedure is identical to the comparative C T procedure described in the ABI PRISM 7700 Sequence Detection System user Bulletin no. 2 for quantitative RT-PCR except that Cp is used, since Roche uses the crossing point procedure instead of crossing threshold to calculate cycles required for detection of mRNA. The calculation of ratios assumes that the number of target molecules doubles with every PCR cycle. The Cp value for each mRNA was corrected for that of cyclophilin, which was used as the control gene and recovery standard. The mean Cp value for cyclophilin in epicardial fat was 26.6±0.4 as the mean ± s.e.m. of 28 runs and did not differ significantly from that for the other fat depots except that the Cp value from SAT abdominal averaged 28.1±0.4. The mean Cp value for cyclophilin in omental adipose tissue was 27.2 ± 0.3 as the mean ± s.e.m. of 29 runs. It is not possible to directly compare the ratios for each gene as compared to cyclophilin with the ratios for other genes because of the relative efficiencies of the particular primers and probes used for each gene are different.
Blood assays
Fasting plasma glucose, glycoslated hemoglobin (HbA1c), lipids and high-sensitivity C-reactive protein (hsCRP) were measured by routine assays in the hospital laboratory.
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Waist circumference
Waist circumference (cm) was measured around the hospital gown-covered abdomen between the lower rib margin and iliac crest mid waist while standing up with heels together.
Statistical analysis
A two-tailed Student's t-test was used to determine whether differences between clinical and metabolic variables were significant at a P-value of o0.05. Statistical analysis of mRNA values was based on the Cp values before log 2 transformation to ratios.
Results
Patient data
The clinical and metabolic characteristics of 14 male and 13 female CAD patients are shown in Table 1 . The men had significantly greater weight (wt), and waist but lower highdensity lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and hsCRP than the women. There was no correlation between epicardial omentin or visfatin mRNA and plasma hsCRP in the pooled MS and DM patients (r ¼ À0.02, P ¼ 0.98 and r ¼ À0.01, P ¼ 0.95, respectively). Ethnicity, MS, DM, smoking, age, body mass index (BMI), HbA1c, fasting plasma glucose, cholesterol and triglycerides were not significantly different. Ten of fourteen (71%) MS and six of thirteen (46%) DM patients were on statins whereas similar proportions were on angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin receptor-blockers, b-blockers and/or antiplatelet drugs in each group (data not shown).
Omentin mRNA expression in epicardial and other adipose tissues The expression of omentin mRNA and visfatin mRNA was examined in the 27 patients with CAD from whom we could obtain epicardial fat, IMA adipose tissue, SAT m. sterni, abdominal SAT and leg SAT (Figure 1 ). There was no statistically significant difference in epicardial fat omentin mRNA between the 14 MS and 13 DM patients (the amount of omentin mRNA in the 14 diabetics was 52 ± 52% greater than that in the 13 MS patients as the means ± s.e.m.), therefore the data were pooled. Similar results were seen for visfatin where the amount of visfatin mRNA in the diabetic patients was 19 ± 20% less than in the MS patients. The amount of omentin mRNA expressed as ratio to cyclophilin in epicardial fat from the 14 males was the same as in that from the 13 females (39 ± 4 and 39 ± 5, respectively) and a similar result was seen for visfatin (11 ± 2 and 11 ± 3). Figure 1 Omentin and visfatin mRNA content in epicardial fat compared to that around the internal mammary artery (IMA), the subcutaneous upper chest fat from the sternotomy incision at the manubrium sterni (SAT m. sterni), the subcutaneous upper abdominal fat at the lower sternotomy incision (SAT abdominal) and subcutaneous leg fat at the vein harvest site (SAT leg). The values are shown as the means±s.e.m. of the ratios of omentin and visfatin mRNA as compared to cyclophilin in each tissue for the 27 coronary artery bypass grafting (CABG) patients. The percent values in the upper half of the graph are omentin mRNA in the various fat depots as percent of that in epicardial fat and these differences were statistically significant (Po0.001). The differences between the other depots were all significant (Po0.001) except for omentin mRNA in IMA versus SAT m. sterni. In contrast there was no significant differences in visfatin mRNA content between the five fat depots.
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Therefore, the data for men and women with and without type 2 diabetes were pooled. Visfatin was used as a control because it has been claimed to be a protein preferentially secreted by visceral fat. 12 Visfatin mRNA in the five fat depots was essentially identical (Figure 1) . In marked contrast, the amount of omentin mRNA in epicardial adipose tissue was at least 20-fold greater than in the other fat depots. The amount of omentin mRNA in the IMA periadventitial fat was 3.5%, that in the SAT m. sterni 4.7%, that in the SAT periadventicial fat abdominal 0.6% and that in the SAT leg was 0.08% of that in epicardial fat (Figure 1 ).
Omentin mRNA distribution in omental fat fractions
We utilized omental fat samples obtained from morbidly obese bariatric patients, as it was not possible to obtain them from the CABG patients. In 13 women with a mean waist circumference of 98 ± 4 cm (mean ± s.e.m., range 69-119 cm), the amount of omentin mRNA was 13-fold greater than that of cyclophilin. This compares to a 39-fold greater amount of omentin mRNA in epicardial adipose tissue as compared to cyclophilin whose content did not differ between the two tissues.
The relative distribution of the mRNAs for omentin and visfatin in the nonfat cells versus the adipocytes, preadipocytes as well as adipocytes differentiated in vitro from preadipocytes of human omental fat examined in four women (Figure 2) . The nonfat cells present in human omental adipose tissue are operationally classified as the SV cells (those that are sedimented by centrifugation while the fat cells are those that float) plus the undigested adipose tissue remaining after collagenase digestion. 8 The omentin mRNA content in the fat cells was 9% while that of visfatin was 25% of that in the nonfat cells (Figure 2 ). The expression of omentin mRNA in cultured preadipocytes derived from omental nonfat cells was less than 0.01% and of visfatin was 3% of that in the freshly isolated nonfat cells (Figure 2 ). Differentiation of preadipocytes in vitro into adipocyte-like cells enhanced the accumulation of omentin mRNA but the amount was still less than 0.3% of that in nonfat cells (Figure 2 ). These data indicate that there is minimal expression of omentin or visfatin mRNA in either freshly isolated fat cells or in vitro differentiated adipocytes.
Discussion
In this study, we identified omentin in human epicardial fat as a novel finding and confirmed that omentin mRNA is present in the nonfat cells of omental fat, unlike leptin and adiponectin that are primarily expressed in adipocytes. 9, 10 The localization of omentin to the nonfat cell fraction is consonant with the report that omentin mRNA is readily detected in endothelial cells in blood vessels of visceral abdominal tissues. 2, 4 The preferential distribution of omentin gene expression in intraabdominal fat and intrathoracic epicardial but not the inner thoracic wall fat, as shown in this study, might be due to the fact that blood vessels and adipocytes of the epicardial as well as the omental depots arise from mesothelial cells of the sphlanchopleuric mesoderm of the gut during development. Visfatin was originally described as an adipokine present only in visceral adipose tissue. 12 However, we and other authors 18, 19 find that it is expressed to the same extent in SAT and visceral fat tissue. Cheng et al. 20 reported that visfatin is release by explants of human epicardial adipose tissue incubated in vitro to about the same extent as by upper Omentin in human epicardial adipose tissue JN Fain et al abdominal SAT. Thus our data on mRNA content are comparable to recent reports [18] [19] [20] indicating that visfatin is an adipokine present in all fat depots of humans. Sampling of the different fat depots permitted us to analyze the expression of the two adipokines in extrathoracic compared to intrathoracic adipose tissue and upper abdominal compared to upper thoracic SAT. Interestingly, omentin mRNA expression is similar in fat around the IMA to that in upper thoracic SAT. In contrast, it decreases from thoracic SAT downwards to leg SAT. Leg SAT was selected as a control depot to epicardial fat first because it abuts the adventitia of the saphenous vein and second because the saphenous vein is not prone to atherosclerosis in its native location and has been reported to have lower levels of periadventitial inflammatory adipokines than epicardial fat. 21 Omental fat from obese humans was used to look at the relative expression of omentin mRNA in the nonfat cells, adipocytes, preadipocytes and in vitro differentiated adipocytes because it is the only visceral adipose tissue depot in humans from which we could obtain sufficient samples expressing high levels of omentin mRNA. The same cell fractionation experiments in epicardial tissue as well as a direct comparison of omentin expression and distribution in epicardial and omental fat from the same patient were prohibited by ethical and safety constraints on sample size and procurement during an operative procedure where the thoracic and peritoneal cavities were not opened simultaneously. Despite this limitation and the fact that the coronary angiographic status of the bariatric surgical patients was unknown, the reason we utilized omental fat from 13 women with a waist circumference of 98 cm was to approximate the waist circumference of 101 cm in the 13 women with CAD.
Yang et al. 5 reported that omentin enhanced Akt phosphorylation in adipocytes, and activation of the Akt signaling pathway by insulin is required for stimulation of glucose transport 22 and endothelial nitric oxide synthase in endothelial cells. 23 Future studies should examine the relationship between endothelial nitric oxide synthase mRNA and omentin mRNA since there is a dysfunction of endothelial nitric oxide synthase in the coronary endothelium of patients with atherosclerosis. 24 Hypothetically, omentin, like other periadventitial epicardial adipokines, might contribute to coronary atherogenesis. 25 It is still unclear whether omentin acts as an insulin-like molecule under physiological conditions. It should also be realized that measurements of omentin mRNA do not necessarily correlate with changes in the amount of omentin. The low amount of omentin in periadventitial adipose tissue from the IMA is commensurate with its embryological derivation from thoracic mesenchyme 26 rendering it phenotypically more like SAT despite its intrathoracic location. This similarity and the low levels of proinflammatory, proatherogenic adipokine expression in SAT from patients with critical CAD compared to their pericoronary epicardial fat 21 offer one explanation inter alia for the reduced proneness of the IMA to atherosclerosis. 27 
